tirzepatide drugs New Breakthrough Obesity Drug Tirzepatide Side Effects: Full Guide

Rated 5 out of 5 Anonymous Verified review - view original it arrived faster than expected even in Alaska Rated 5 out of 5 Matheus D

SURMOUNT-1 results In this 72-week obesity trial, participants receiving tirzepatide achieved remarkable weight loss results: 5 mg dose: 85% achieved at least 5% weight reduction, with average weight loss of 15% 10 mg dose: 89% achieved at least 5% weight reduction, with average weight loss of 19% 15 mg dose: 91% achieved at least 5% weight reduction, with average weight loss of 21% These results were achieved with consistent weekly dosing

It is also expected that obesity in the US is going to increase to 46.9% by 2035

Semaglutide belongs to a class of medications known as GLP-1 (glucagon-like peptide-1) receptor agonists